Tipifarnib: farnesyl transferase inhibition at a crossroads

Expert Review of Anticancer Therapy
Ruben A Mesa

Abstract

Tipifarnib is an oral nonpeptidomimetic farnesyl transferase inhibitor developed to inhibit a variety of farnesylated targets potentially relevant to the therapy of various malignancies. The agent has, thus far, been tested in a wide array of both solid tumors and myeloid malignancies. Phase I trials have demonstrated that tipifarnib is best given in a twice-daily fashion in doses of 600-1200 mg/day to avoid significant neuropathy, fatigue and myelosuppression. Subsequent trials demonstrated that pauses in therapy (with staccato dosing schedules) seem to increase tolerability without a clear decrease in efficacy. Phase II and III trials of tipifarnib as monotherapy for breast, colorectal, lung (both non-small cell and small cell), brain, pancreatic and urothelial cancers have all been disappointing. Combination trials of tipifarnib with cytotoxic, hormonal or biological therapies are ongoing. Tipifarnib has displayed the most interesting activity in the myeloid malignancies of myelodysplastic syndrome, myelofibrosis with myeloid metaplasia and elderly/high-risk acute myeloid leukemia. Overall clinical response rates of approximately 20-30% have been reported in myelodysplastic syndrome and acute myeloid leukemia patients who ha...Continue Reading

References

Jan 1, 1996·Annual Review of Biochemistry·F L Zhang, P J Casey
Jan 1, 1997·Annual Review of Pharmacology and Toxicology·J B Gibbs, A Oliff
Nov 25, 1997·Current Opinion in Oncology·S Sebti, A D Hamilton
Jul 17, 1998·Current Opinion in Chemical Biology·M H GelbJ S Sebolt-Leopold
Mar 10, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D M Beaupre, R Kurzrock
Nov 5, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E K RowinskyD D Von Hoff
Feb 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J ZujewskiK H Cowan
Apr 13, 2000·Biochimica Et Biophysica Acta·M Sinensky
Apr 27, 2000·The New England Journal of Medicine·A Tefferi
Apr 5, 2001·The New England Journal of Medicine·B J DrukerC L Sawyers
Jul 19, 2001·Journal of the National Cancer Institute·A A Adjei
Oct 24, 2001·Current Opinion in Oncology·J E KarpD W End
May 2, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alex A AdjeiEverett E Vokes
Jun 24, 2003·Blood Reviews·Jeffrey E Lancet, Judith E Karp
Jun 28, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen R D JohnstonAngela Howes
Mar 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Razelle KurzrockHagop M Kantarjian
Apr 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E Van CutsemD Von Hoff
Jul 28, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J V HeymachB E Johnson
Oct 2, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S RaoP A Palmer
Jun 23, 2005·Frontiers in Bioscience : a Journal and Virtual Library·M CaragliaA Abbruzzese

❮ Previous
Next ❯

Citations

May 29, 2010·Amino Acids·Thiruvengadam Arumugam, Craig D Logsdon
Feb 3, 2011·The Journal of Clinical Investigation·Ignacio Munoz-Sanjuan, Gillian P Bates
Dec 3, 2013·Neurosurgical Focus·Alan A MoazzamGabriel Zada
Oct 11, 2011·Cellular and Molecular Life Sciences : CMLS·Francisco Javier Rodríguez-Jiménez, Victoria Moreno-Manzano
May 12, 2007·Expert Review of Anticancer Therapy·Marta Penas-Prado, Mark R Gilbert
Jul 3, 2007·Expert Opinion on Emerging Drugs·Yesid Alvarado, Francis J Giles
May 1, 2007·Clinical Biochemistry·Irina Buhaescu, Hassane Izzedine
Mar 19, 2008·Journal of the Peripheral Nervous System : JPNS·Anthony J Windebank, Wolfgang Grisold
Aug 11, 2015·Advances in Biological Regulation·Timothy L FitzgeraldJames A McCubrey
Sep 12, 2016·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Manoj KumarD K Dhawan
Jun 7, 2008·The Journal of International Medical Research·J RedzepovicR Gust
Jul 28, 2007·International Journal of Cancer. Journal International Du Cancer·Michele CaragliaPierosandro Tagliaferri
Feb 2, 2021·Expert Opinion on Pharmacotherapy·Anna Wolska-WasherTadeusz Robak
Mar 26, 2021·Seminars in Liver Disease·Yi ZhangDiego F Calvisi
Jul 9, 2021·Proceedings of the National Academy of Sciences of the United States of America·Woo Dae JangSang Yup Lee
May 2, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Dinesh Kumar ChellappanKamal Dua

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Related Papers

Expert Opinion on Investigational Drugs
Floriana Morgillo, Ho-Young Lee
Biochemical and Biophysical Research Communications
Alessandro PalmioliM Vanoni
© 2021 Meta ULC. All rights reserved